Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Retained Earnings (2016 - 2026)

Aytu Biopharma has reported Retained Earnings over the past 15 years, most recently at -$342.2 million for Q4 2025.

  • Quarterly Retained Earnings fell 7.69% to -$342.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$342.2 million through Dec 2025, down 7.69% year-over-year, with the annual reading at -$333.5 million for FY2025, 4.24% down from the prior year.
  • Retained Earnings was -$342.2 million for Q4 2025 at Aytu Biopharma, down from -$331.6 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$178.3 million in Q2 2021 and troughed at -$342.2 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$312.2 million (2023), against an average of -$292.9 million.
  • Year-over-year, Retained Earnings plummeted 65.87% in 2021 and then grew 0.52% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$217.7 million in 2021, then tumbled by 35.27% to -$294.5 million in 2022, then decreased by 6.11% to -$312.5 million in 2023, then fell by 1.68% to -$317.7 million in 2024, then dropped by 7.69% to -$342.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Retained Earnings are -$342.2 million (Q4 2025), -$331.6 million (Q3 2025), and -$333.5 million (Q2 2025).